Cxbladder Resolve单独及联合其他Cxbladder检测在尿路上皮癌风险评估中的诊断性能
本研究验证Cxbladder Resolve(CxbR)识别高影响肿瘤(HIT)的诊断性能,并验证Cxbladder系列检测算法区分高影响与低影响肿瘤的能力。CxbR在863例血尿患者中开发,在548例美国前瞻性观察研究中验证。结果显示CxbR敏感性和特异性高,序贯检测正确排除87.6%患者(阴性预测值99.4%),所有HIT均被正确识别。
要点
- CxbR识别HIT的敏感性92.4%、特异性93.8%(开发集)
- 外部验证中序贯Cxb检测排除87.6%患者,阴性预测值99.4%
- 序贯检测正确识别100%的HIT,特异性96.3%
核心结论
- CxbR具有高敏感性和特异性,能正确识别所有HIT。
- 序贯Cxb检测能准确区分低概率与高概率HIT患者,将资源集中于高风险患者。
- 序贯Cxb检测的诊断产出比AUA指南分层高4.8倍。
研究设计与样本
- CxbR在3项来自美国、澳大利亚和新西兰的研究中863例血尿患者中开发。
- CxbR单独及联合其他Cxb检测在美国一项前瞻性观察研究中548例血尿患者中验证。
- 所有UC诊断均经组织病理学确认。
主要发现
- 开发数据集中,CxbR识别高优先类别中HIT的敏感性为92.4%(95% CI 83.3-96.7),特异性为93.8%(95% CI 86.8-97.2)。
- 外部验证中,序贯Cxb检测正确排除87.6%患者进一步检查(阴性预测值99.4%)。
- 外部验证中,100%的HIT被正确识别(特异性96.3%),遗漏3例低级别肿瘤。
- 两项研究中,所有HIT患者均被正确分配至优先评估。
临床怎么用
- 对于血尿患者,可序贯使用CxbT、CxbD和CxbR检测,以识别高概率HIT患者并优先评估。
- 序贯Cxb检测阴性预测值高,有助于减少不必要的进一步检查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cxbladder (Cxb) tests combine genomic biomarkers in urine with phenotypic and clinical data to classify hematuria patients into those at low/high probability of urothelial carcinoma (UC). Cxbladder Resolve (CxbR) is designed for use after Cxb Triage (CxbT) and Detect (CxbD), where CxbT-positive tests reflex to CxbD and CxbD-positive to CxbR to identify patients at high probability of high-impact tumors (HIT; high grade Ta, Tis or T1-T3). This study validated the diagnostic performance of CxbR in identifying HIT, and validated the algorithm of Cxb tests to segregate high-impact from low-impact tumors. MATERIALS AND METHODS: CxbR was developed in 863 hematuria patients in 3 studies in United States, Australia and New Zealand. CxbR, separately and combined with other Cxb tests, was validated in a prospective, observational U.S. study in 548 hematuria patients. All UC diagnoses were confirmed by histopathology. RESULTS: In the development data set, CxbR sensitivity was 92.4% (95% CI 83.3-96.7) and specificity 93.8% (95% CI 86.8-97.2) for identifying HIT within the high priority category. During external validation, sequential Cxb tests correctly ruled out 87.6% of patients from further workup (negative predictive value 99.4%); 100% of HIT were correctly identified (specificity 96.3%), and 3 low-grade tumors were missed. In both studies, all patients with HIT were correctly assigned to prioritized evaluation. CONCLUSIONS: CxbR has high sensitivity and specificity, correctly identifying all HIT. Sequential Cxb tests accurately segregate patients with a low vs high probability of HIT, focusing resources on those patients, with a diagnostic yield 4.8-fold higher than American Urological Association guideline stratification.
引用
- Raman JD, Kavalieris L, Konety B, et al. The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma. J Urol. 2021. PMID: 34348469. doi:10.1097/JU.0000000000002135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。